Codelac broncho Table 10 pc

$3.91

Codelac broncho Table 10 pc

Quantity:

SKU: 1879442868 Categories: , , Tags: ,

Description

Composition
Active substance:
1 tablet contains: ambroxol hydrochloride (Ambroxol) – 20.0 mg, glycyrrhizic acid trisodium salt (sodium glycyrrhizinate) – 30.0 mg, termopsisa dry extract – 10.0 mg Sodium hydrogencarbonate – 200.0 mg.
Excipients:
Potato starch – 84.30 mg, Microcrystalline Cellulose – 150.10 mg Povidone (polyvinylpyrrolidone, povidone K25) -26.40 mg talc – 13.00 mg stearic acid – 5.20 mg sodium carboxymethyl starch (sodium starch glycolate ) – 11.00 mg.
Description:
Valium tablets from light cream to cream to yellowish shade with darker and lighter patches, with Valium and a facet.
Product form:
Tablets.
10 tablets in blisters. 1 or 2 blisters with instructions for use in a cardboard pack.
Contraindications
Hypersensitivity to the drug, pregnancy, lactation, children under 12 years.
Precautions: hepatic and / or renal failure, gastric ulcer and 12 tiperstnoj ulcers, bronchial asthma.
Dosage
20 mg + 200 mg + 30 mg + 10 mg
Indications
airways disease with difficulty sputum discharge, acute and chronic bronchitis, pneumonia, chronic obstructive pulmonary disease (COPD), bronchiectasis.
Interaction with other drugs
Joint application with antitussive drugs leads to difficulty in expectoration background reducing cough.
The drug increases the penetration of the bronchial secretion of antibiotics.
Overdose
Symptoms include nausea, vomiting, diarrhea, dyspepsia.
Treatment is symptomatic, gastric lavage expedient in the first 1-2 hours after ingestion.
pharmachologic effect
Pharmacological group:
Expectorant combined means.
Pharmacodynamics:
A combined preparation for the treatment of cough, has mucolytic and expectorant action and also has anti-inflammatory activity.
Action Codelac® Broncho due to the pharmacological properties of its components:
Ambroxol has secretomotoric, sekretoliticheskim and expectorant action, it normalizes the disturbed ratio of serous and mucous sputum components increases the secretion of surfactant in the alveoli. It decreases sputum viscosity and facilitates its expectoration.
Glitsirrat (glycyrrhizic acid and its salts) possesses anti-inflammatory and antiviral action. It has a cytoprotective effect through antioxidant and membrane stabilizing activity. It potentiates the action of endogenous glucocorticoids, providing anti-inflammatory and anti-allergic effect. Due to the pronounced anti-inflammatory activity, it helps to reduce inflammation in the airways.
Extract termopsisa has expectorant action, exerting a mild irritant action on gastric mucosal receptors reflex increases secretion of bronchial glands.
Sodium hydrogen shifts the indicator medium (pH) bronchial mucus in the alkaline side, reduces the viscosity of sputum, stimulates the motor function of the ciliated epithelium and bronchial tubes.
Pharmacokinetics:
Ambroxol.
Suction. For ambroxol is characterized by rapid and almost complete absorption from the gastrointestinal tract. The bioavailability is 70-80%. Maximum plasma concentration achieved after oral administration is 1-3 hours. Binding to plasma proteins is 80-90%.
Distribution. Going ambroxol from blood to tissue when administered happens quickly. The highest concentration of active ingredient of the drug are observed in the lungs. It penetrates the blood-brain barrier, the placental barrier, excreted in breast milk.
Metabolism. Approximately 30% of an oral dose is exposed to the effect of “first pass” through the liver. Studies in human liver microsomes have shown that CYP3A4 isoenzyme is predominant isoenzyme responsible for the metabolism of ambroxol. The remainder of ambroxol is metabolized in the liver to inactive metabolites.
Withdrawal. The half-life (T 1/2) of ambroxol is about 10 hours. Excreted by the kidneys 90% as metabolites, 10% unchanged.
Pharmacokinetics in special patient groups.
Not detected clinically significant effect of age and gender on the pharmacokinetics of ambroxol, there is no reason for dose adjustment for these characters. Clearance of ambroxol in patients with severe hepatic impairment is reduced by 20-40%.
In severe renal insufficiency T 1/2 ambroxol metabolites increases.
Trisodium salt of glycyrrhizic acid (glycyrrhizinate sodium).
After oral administration, the intestine under the influence of the enzyme beta-glucuronidase produced by bacteria of normal microflora of glycyrrhizic acid is formed active metabolite – beta -glitsirretovaya acid which is absorbed into the systemic circulation. Blood beta glycyrrhetic acid is bound to albumin, and is almost entirely transported to the liver. Isolation of beta-glycyrrhetic acid occurs predominantly in bile, in the residual amount – the urine.
Thermopsis dry extract.
extract components are well absorbed in the gastrointestinal tract. Maximum action occurs within 30-60 minutes after oral administration and lasts for 2-6 hours. Excreted by the kidneys, the respiratory tract mucosa and bronchial glands.
Sodium bicarbonate.
Well absorbed from the gastrointestinal tract. Maximum action occurs within 30-60 minutes after oral administration and lasts for 2-6 hours. Excreted by the kidneys, the respiratory tract mucosa and bronchial glands.
Pregnancy and breast-feeding
Use of the drug during pregnancy is contraindicated. If necessary, use during lactation should stop breastfeeding.
Conditions of supply of pharmacies
Without recipe.
side effects
Allergic reactions. Rarely – weakness, headache, diarrhea, dry mouth and respiratory tract, rash, runny nose, constipation, dysuria. Chronic administration of high doses – gastralgia, nausea, vomiting.
special instructions
Not combined with antitussive agents.
Effects on ability to drive vehicles, mechanisms:
It is not known cases of drug effects on the ability to drive and use machines. Appropriate studies have not been conducted.
Storage conditions
Store at a temperature not higher than 25 ° C. Keep out of the reach of children.
Dosing and Administration
Inside, during a meal. 1 tablet 3 times a day for adults and children over 12 years. Not recommended for use without a doctor’s appointment more than 4-5 days.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

OTISIFARM

There are no reviews yet.

Add your review